flurizan rflurbiprofen single enantiomer racemate nsaid flurbiprofen several years research trials drug conducted myriad genetics investigate potential treatment alzheimers disease investigation concluded june company announced would discontinue development proposed therapeutic concentrations molecule lacks antiinflammatory activity inhibit either cyclooxygenase cyclooxygenase enzymes senantiomers arylpropionic acid nsaid potently inhibit cox whereas renantiomers exert almost cox activity rflurbiprofen inefficiently converted sflurbiprofen renantiomer undergoing bioinversion sform although compound lacks activity cox studies shown drug potent reducer levels beta main constituent amyloid plaques alzheimers disease therefore interest drug therapeutic agent myriad genetics reported results phase ii clinical trial flurizan largest ever alzheimers drug treatment trial using patients split three treatment groups receiving placebo mg rflurbiprofen twice daily year result trial showed drug well tolerated positive trends observed mg twicedaily dose patients mild alzheimers disease subgroup patients diagnosed mild disease high plasma drug levels significantly less decline two primary behavioral outcomes activities daily living scale adcsadl global function cdrsb approximately patients enrolled optional followon study showed continuing benefits rflurbiprofen increasing positive trends period primary outcomes months march myriad reported final results twoyear trial showing patients showed improvement decline one three primary endpoints cognition global function activities daily living compared typical patients placebo phase iii clinical study evaluated mg rflurbiprofen twicedaily versus placebo months exclusively patients mild alzheimers second trial concluded february results reported summer phase iii testing included nearly patients mild alzheimer disease treated months either flurizan placebo myrial genetics concluded drug improve thinking ability ability patients carry daily activities significantly patients placebo peter meldrum chief executive myriad announced june company longer developing prior termination myriad sold distribution rights european union lundbeck initial payment million lundbeck indicated take httpsenwikipediaorgwikitarenflurbil